The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
News|Videos|November 21, 2025
Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer: Five-Year and Post-(Neo)Adjuvant Outcomes From KEYNOTE-775 and LEAP-001
Author(s)Christian Marth, MD, PhD
Christian Marth, MD, PhD discusses long-term efficacy and safety results from KEYNOTE-775 and LEAP-001. Data include patients with advanced or recurrent endometrial cancer after prior systemic therapy. Follow-up duration was approximately 5 years for KEYNOTE-775 and 4 years for LEAP-001.
Advertisement
Advertisement
Related to this article
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
Bringing some or all clinical trial-related activities directly to patients can help overcome barriers that prevent many people from participating.
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.
High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
4
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
5